WRN 螺旋酶：MSI-H 不只是免疫疗法？

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-08-02 DOI:10.1158/2159-8290.CD-24-0771

Zev A Wainberg

{"title":"WRN 螺旋酶：MSI-H 不只是免疫疗法？","authors":"Zev A Wainberg","doi":"10.1158/2159-8290.CD-24-0771","DOIUrl":null,"url":null,"abstract":"In this issue, Picco and colleagues provide further evidence that WRN inhibitors are synthetically lethal in microsatellite instability-high (MSI-H) cancers and function by blocking the helicase domain of select WRN residues. They demonstrate that WRN inhibitors may be even more effective in a subset of MSI-high tumors with (TA)n repeat expansions, which represents a possible strategy in clinical development. See related article by Picco et al., p. 1457 (1).","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"14 8","pages":"1369-1371"},"PeriodicalIF":29.7000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"WRN Helicase: Is There More to MSI-H than Immunotherapy?\",\"authors\":\"Zev A Wainberg\",\"doi\":\"10.1158/2159-8290.CD-24-0771\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this issue, Picco and colleagues provide further evidence that WRN inhibitors are synthetically lethal in microsatellite instability-high (MSI-H) cancers and function by blocking the helicase domain of select WRN residues. They demonstrate that WRN inhibitors may be even more effective in a subset of MSI-high tumors with (TA)n repeat expansions, which represents a possible strategy in clinical development. See related article by Picco et al., p. 1457 (1).\",\"PeriodicalId\":9430,\"journal\":{\"name\":\"Cancer discovery\",\"volume\":\"14 8\",\"pages\":\"1369-1371\"},\"PeriodicalIF\":29.7000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2159-8290.CD-24-0771\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-24-0771","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在本期杂志中，Picco及其同事提供了进一步的证据，证明WRN抑制剂对微卫星不稳定性高（MSI-H）癌症具有合成致死性，并通过阻断特定WRN残基的螺旋酶结构域发挥作用。他们证明，WRN抑制剂对具有(TA)n重复扩增的MSI-高肿瘤亚群可能更有效，这代表了一种可能的临床开发策略。参见 Picco 等人的相关文章，第 1457 页(1)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

WRN Helicase: Is There More to MSI-H than Immunotherapy?

In this issue, Picco and colleagues provide further evidence that WRN inhibitors are synthetically lethal in microsatellite instability-high (MSI-H) cancers and function by blocking the helicase domain of select WRN residues. They demonstrate that WRN inhibitors may be even more effective in a subset of MSI-high tumors with (TA)n repeat expansions, which represents a possible strategy in clinical development. See related article by Picco et al., p. 1457 (1).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.